Total Payments
$58,345
2024 Payments
$20.92
Companies
49
Transactions
329
Medicare Patients
3,442
Medicare Billing
$429,720
Payment Breakdown by Category
Research$53,042 (90.9%)
Food & Beverage$5,303 (9.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53,042 | 18 | 90.9% |
| Food and Beverage | $5,303 | 311 | 9.1% |
Payments by Type
Research
$53,042
18 transactions
General
$5,303
311 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $51,738 | 38 | $0 (2020) |
| Allergan, Inc. | $1,748 | 14 | $0 (2020) |
| UCB, Inc. | $673.77 | 30 | $0 (2020) |
| Supernus Pharmaceuticals, Inc. | $532.36 | 28 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $388.20 | 21 | $0 (2019) |
| GENZYME CORPORATION | $358.25 | 19 | $0 (2019) |
| Shire North American Group Inc | $337.04 | 18 | $0 (2019) |
| Eisai Inc. | $275.22 | 15 | $0 (2020) |
| Biogen, Inc. | $230.71 | 25 | $0 (2019) |
| Lundbeck LLC | $192.07 | 11 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.92 | 1 | Neurelis, Inc. ($20.92) |
| 2020 | $450.59 | 19 | Boston Scientific Corporation ($92.38) |
| 2019 | $1,784 | 104 | Novartis Pharmaceuticals Corporation ($277.59) |
| 2018 | $15,586 | 86 | ACADIA Pharmaceuticals Inc ($14,157) |
| 2017 | $40,504 | 119 | ACADIA Pharmaceuticals Inc ($37,446) |
All Payment Transactions
329 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/23/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: EPILEPSY | ||||||
| 10/22/2020 | Boston Scientific Corporation | GENERAL - PAIN MANAGEMENT (Device) | Food and Beverage | In-kind items and services | $92.38 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/16/2020 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: NEUROLOGY | ||||||
| 02/27/2020 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Immunology | ||||||
| 02/27/2020 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $21.47 | General |
| 02/25/2020 | Jazz Pharmaceuticals Inc. | SUNOSI (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: NEUROLOGY | ||||||
| 02/24/2020 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $16.41 | General |
| Category: AED | ||||||
| 02/21/2020 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: Neurology | ||||||
| 02/20/2020 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $16.79 | General |
| Category: NEUROLOGY | ||||||
| 02/18/2020 | Greenwich Biosciences, Inc. | Epidiolex (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Neurology | ||||||
| 02/13/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $11.34 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/10/2020 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Genetic Disease | ||||||
| 02/07/2020 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $16.88 | General |
| 02/04/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2020 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $18.80 | General |
| Category: NEUROLOGY | ||||||
| 01/15/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/14/2020 | PORTOLA PHARMACEUTICALS, LLC | ANDEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $13.29 | General |
| Category: HEMATOLOGY/NEUROLOGY | ||||||
| 01/13/2020 | Eisai Inc. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $21.94 | General |
| Category: Neurology | ||||||
| 01/06/2020 | Kyowa Kirin, Inc. | NOURIANZ (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: ADENOSINE A2A RECEPTORS | ||||||
| 01/01/2020 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $20.33 | General |
| 12/23/2019 | EISAI INC. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $20.29 | General |
| Category: Neurology | ||||||
| 12/17/2019 | Adlon Therapeutics L.P. | ADHANSIA XR (Drug) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: PRESCRIPTION STIMULANT | ||||||
| 12/10/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: HYPERHYDROSIS | ||||||
| 12/09/2019 | Upsher-Smith Laboratories LLC | QUDEXY XR Topiramate Extended Release Capsules (Drug), Zembrace SymTouch Sumatriptan Injection, Tosymra Sumatriptan Nasal Spray | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Neurology | ||||||
| 12/05/2019 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $25,856 | 3 |
| ACP-103-048 | ACADIA Pharmaceuticals Inc | $9,500 | 1 |
| ACP-103-032 | ACADIA Pharmaceuticals Inc | $8,093 | 6 |
| ACP-103-033 | ACADIA Pharmaceuticals Inc | $6,000 | 2 |
| ACP-103-015 | ACADIA Pharmaceuticals Inc | $2,000 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $976.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $616.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 863 | 1,140 | $529,864 | $111,278 |
| 2022 | 11 | 852 | 1,128 | $523,050 | $111,505 |
| 2021 | 12 | 908 | 1,174 | $365,894 | $114,378 |
| 2020 | 10 | 819 | 1,052 | $294,900 | $92,559 |
Total Patients
3,442
Total Services
4,494
Medicare Billing
$429,720
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 334 | 505 | $185,840 | $49,218 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 127 | 127 | $64,008 | $15,770 | 24.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 71 | 73 | $40,369 | $10,181 | 25.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 152 | $30,096 | $10,038 | 33.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 37 | $18,944 | $5,042 | 26.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 22 | $16,060 | $3,791 | 23.6% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 80 | 84 | $93,240 | $3,722 | 4.0% |
| 95719 | Measurement of brain wave activity (eeg), 12-26 hours with health care professional review and report | Office | 2023 | 21 | 21 | $13,020 | $2,805 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 23 | $9,430 | $2,736 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 15 | 15 | $7,755 | $2,083 | 26.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 16 | 26 | $10,868 | $2,051 | 18.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 16 | $6,096 | $1,610 | 26.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 25 | 28 | $31,080 | $1,324 | 4.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 11 | $3,058 | $906.51 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 320 | 507 | $179,448 | $50,208 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 122 | 122 | $59,352 | $16,784 | 28.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 84 | 85 | $45,315 | $13,504 | 29.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 82 | 152 | $29,061 | $9,173 | 31.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 35 | $17,368 | $5,163 | 29.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 80 | 85 | $90,693 | $4,116 | 4.5% |
| 95719 | Measurement of brain wave activity (eeg), 12-26 hours with health care professional review and report | Office | 2022 | 23 | 24 | $14,280 | $3,166 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $7,972 | $2,195 | 27.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 42 | 43 | $45,928 | $2,017 | 4.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 15 | $5,890 | $1,868 | 31.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 11 | 16 | $6,528 | $1,368 | 21.0% |
About Dr. Robert Bonwetsch, MD
Dr. Robert Bonwetsch, MD is a Neurology healthcare provider based in Danbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801856687.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Bonwetsch, MD has received a total of $58,345 in payments from pharmaceutical and medical device companies, with $20.92 received in 2024. These payments were reported across 329 transactions from 49 companies. The most common payment nature is "" ($53,042).
As a Medicare-enrolled provider, Bonwetsch has provided services to 3,442 Medicare beneficiaries, totaling 4,494 services with total Medicare billing of $429,720. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Danbury, CT
- Active Since 03/24/2006
- Last Updated 03/21/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1801856687
Products in Payments
- NUPLAZID (Drug) $51,738
- TROKENDI XR (Drug) $532.36
- Briviact (Drug) $513.27
- Fycompa (Drug) $275.22
- VYVANSE (Drug) $210.22
- AIMOVIG (Biological) $197.05
- NORTHERA (Drug) $178.03
- APTIOM (Drug) $177.90
- Gamunex-C (Biological) $163.71
- LEMTRADA (Drug) $160.70
- Vimpat (Drug) $160.50
- GILENYA (Drug) $143.14
- TECFIDERA (Drug) $135.19
- MYDAYIS (Drug) $126.82
- NUEDEXTA (Drug) $126.56
- AUBAGIO (Drug) $120.48
- VNS Therapy (Device) $92.97
- GENERAL - PAIN MANAGEMENT (Device) $92.38
- Rebif (Biological) $83.66
- POMPE - DISEASE (Drug) $77.07
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Danbury
Dr. David Greco, M.d, M.D
Neurology — Payments: $155,265
Neurology $155,265
Victor Ylagan, Md, MD
Neurology — Payments: $22,148
Neurology $22,148
Dr. Samuel Markind, M.d, M.D
Neurology — Payments: $21,000
Neurology $21,000
Behzad Habibi Khameneh, M.d, M.D
Neurology — Payments: $7,092
Neurology $7,092
Dr. Neil Culligan, M.d, M.D
Neurology — Payments: $3,123
Neurology $3,123
Dr. Diane Wirz, M.d, M.D
Neurology — Payments: $1,891
Neurology $1,891